Expansion and characterization of neonatal cardiac pericytes provides a novel cellular option for tissue engineering in congenital heart disease

Journal of the American Heart Association

Volumn 4, Issue 6, 2015, Pages

  Avolio, Elisa ^a   Rodriguez Arabaolaza, Iker ^a   Spencer, Helen L ^a   Riu, Federica ^a   Mangialardi, Giuseppe ^a   Slater, Sadie C ^a   Rowlinson, Jonathan ^a   Alvino, Valeria V ^a   Idowu, Oluwasomidotun O ^a   Soyombo, Stephanie ^a   Oikawa, Atsuhiko ^a   Swim, Megan M ^a   Kong, Cherrie H T ^a   Cheng, Hongwei ^a   Jia, Huidong ^a   Ghorbel, Mohamed T ^a   Hancox, Jules C ^a   Orchard, Clive H ^a   Angelini, Gianni ^a,b   Emanueli, Costanza ^a,b   Caputo, Massimo ^a   Madeddu, Paolo ^a   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cells; Congenital heart defects; Grafting; Myocardium; Pediatrics

Indexed keywords

CD146 ANTIGEN; CD34 ANTIGEN; CHEMOATTRACTANT; COLLAGEN TYPE 1; MATRIGEL; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; CULTURE MEDIUM;

ANGIOGENESIS; ARTICLE; C KIT+ CARDIAC PROGENITOR CELL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CLONOGENESIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HEART GRAFT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; INFANT; MESENCHYME CELL; NEWBORN; NEWBORN CARE; PALLIATIVE THERAPY; PARACRINE SIGNALING; PERICYTE; PRESCHOOL CHILD; RECONSTRUCTIVE SURGERY; SPINDLE CELL; TISSUE ENGINEERING; VASCULAR SMOOTH MUSCLE CELL; XENOGRAFT; CULTURE MEDIUM; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HEART DEFECTS, CONGENITAL; PHYSIOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL; TISSUE TRANSPLANTATION;

CULTURE MEDIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; PERICYTES; REAL-TIME POLYMERASE CHAIN REACTION; STEM CELLS; TISSUE ENGINEERING; TISSUE TRANSPLANTATION;

EID: 85018199859     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002043     Document Type: Article

References (29)

1. Khoshnood B, Lelong N, Houyel L, Thieulin AC, Jouannic JM, Magnier S, Delezoide AL, Magny JF, Rambaud C, Bonnet D, Goffinet F; Group ES. Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study. Heart. 2012;98:1667–1673.
2. Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet. 2010;375:649– 656.
3. McElhinney DB. Recent progress in the understanding and management of postoperative right ventricular outflow tract dysfunction in patients with congenital heart disease. Circulation. 2012;125:e595–e599.
4. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, Berger S, Frommelt MA, Lewis DA, Friedberg DZ, Thomas JP Jr, Sachdeva R, Litwin SB. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circula-tion. 2000;102:III130–III135.
5. Bernstein HS, Srivastava D. Stem cell therapy for cardiac disease. Pediatr Res. 2012;71:491–499.
6. Pincott ES, Burch M. Potential for stem cell use in congenital heart disease. Future Cardiol. 2012;8:161–169.
7. Scholl FG, Boucek MM, Chan KC, Valdes-Cruz L, Perryman R. Preliminary experience with cardiac reconstruction using decellularized porcine extracel-lular matrix scaffold: human applications in congenital heart disease. World J Pediatr Congenit Heart Surg. 2010;1:132–136.
8. Bertipaglia B, Ortolani F, Petrelli L, Gerosa G, Spina M, Pauletto P, Casarotto D, Marchini M, Sartore S; Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur P. Cell characterization of porcine aortic valve and decellularized leaflets repopulated with aortic valve interstitial cells: the VESALIO Project (Vitalitate Exornatum Succedaneum Aorticum Labore Ingeni-oso Obtenibitur). Ann Thorac Surg. 2003;75:1274–1282.
9. Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, Shinoka T. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010;139:431–436, 436.e1–2.
10. Cebotari S, Tudorache I, Schilling T, Haverich A. Heart valve and myocardial tissue engineering. Herz. 2010;35:334–341.
11. Dohmen PM, Lembcke A, Holinski S, Pruss A, Konertz W. Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg. 2011;92:1308–1314.
12. Vono R, Spinetti G, Gubernator M, Madeddu P. What’s new in regenerative medicine: split up of the mesenchymal stem cell family promises new hope for cardiovascular repair. J Cardiovasc Transl Res. 2012;5:689–699.
13. Nees S, Weiss DR, Juchem G. Focus on cardiac pericytes. Pflugers Arch. 2013;465:779–787.
14. Chen WC, Baily JE, Corselli M, Diaz M, Sun B, Xiang G, Gray GA, Huard J, Peault B. Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells. 2015;33:557–573.
15. Invernici G, Emanueli C, Madeddu P, Cristini S, Gadau S, Benetti A, Ciusani E, Stassi G, Siragusa M, Nicosia R, Peschle C, Fascio U, Colombo A, Rizzuti T, Parati E, Alessandri G. Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol. 2007;170:1879–1892.
16. Campagnolo P, Cesselli D, Al Haj Zen A, Beltrami AP, Krankel N, Katare R, Angelini G, Emanueli C, Madeddu P. Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. Circulation. 2010;121:1735–1745.
17. Klein D, Weisshardt P, Kleff V, Jastrow H, Jakob HG, Ergun S. Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation. PLoS One. 2011;6: e20540.
18. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301–313.
19. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, Fortunato O, Avolio E, Cesselli D, Beltrami AP, Angelini G, Emanueli C, Madeddu P. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res. 2011;109:894–906.
20. Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D’Aurizio F, Verardo R, Piazza S, Pignatelli A, Poz A, Baccarani U, Damiani D, Fanin R, Mariuzzi L, Finato N, Masolini P, Burelli S, Belluzzi O, Schneider C, Beltrami CA. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood. 2007;110:3438–3446.
21. Smits AM, van Vliet P, Metz CH, Korfage T, Sluijter JP, Doevendans PA, Goumans MJ. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc. 2009;4:232–243.
22. Cheng H, Lederer WJ, Cannell MB. Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science. 1993;262:740–744.
23. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126:S54–S64.
24. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marban L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC, Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63:110–122.
25. Wanjare M, Kuo F, Gerecht S. Derivation and maturation of synthetic and contractile vascular smooth muscle cells from human pluripotent stem cells. Cardiovasc Res. 2013;97:321–330.
26. Avolio E, Meloni M, Spencer HL, Riu F, Katare R, Mangialardi G, Oikawa A, Rodriguez-Arabaolaza I, Dang Z, Mitchell K, Reni C, Alvino VV, Rowlinson J, Livi U, Cesselli D, Angelini G, Emanueli C, Beltrami AP, Madeddu P. Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. Circ Res. 2015;116:e81–e94.
27. Wehman B, Kaushal S. The emergence of stem cell therapy for patients with congenital heart disease. Circ Res. 2015;116:566–569.
28. Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116:653–664.
29. Kawamura H, Kobayashi M, Li Q, Yamanishi S, Katsumura K, Minami M, Wu DM, Puro DG. Effects of angiotensin II on the pericyte-containing microvas-culature of the rat retina. J Physiol. 2004;561:671–683.